Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008

Monday, December 1, 2008 General News J E 4
BASKING RIDGE, N.J., Dec. 1 Regado Biosciences, Inc.,announced today David J. Mazzo, Ph.D., President and Chief Executive Officer,will present at the 20th Annual Piper Jaffray Health Care Conference in NewYork, NY, on Tuesday, December 2, 2008, at 10:10am (Eastern Standard Time).Dr. Mazzo will discuss the Company's development pipeline, in addition toreviewing recent business and clinical developments.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the creationand development of two-component drug systems, comprising an aptamertherapeutic that can be controlled directly by its specific and matchedreversal agent. Regado's technology is designed to give physicians theability to directly control and titrate each system's therapeutic effect.Enhanced control and flexibility allow physicians to meet the individual needsof patients independent of the setting. Regado is focusing its discovery anddevelopment efforts on acute care injectable antithrombotics, a multi-billiondollar market in need of therapeutics with improved safety profiles and agreater degree of therapeutic control.

Current investors in Regado include Domain (Princeton, NJ), QuakerBioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton AdvantageLife Sciences Fund (New York, NY), as well as individual investors, includingRobert Kierlin.

SOURCE Regado Biosciences


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Acuo Technologies Announces Vendor Neutral Archivi...
QLT to repurchase up to US$ 50 million of common s...